VYNE Therapeutics Inc.
VYNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $1 |
| % Growth | 18.2% | -11.1% | -48.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $31 | $16 | $18 | $20 |
| G&A Expenses | $13 | $13 | $16 | $0 |
| SG&A Expenses | $13 | $13 | $16 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $44 | $30 | $35 | $40 |
| Operating Income | -$44 | -$29 | -$34 | -$39 |
| % Margin | -8,710% | -6,900.5% | -7,189.7% | -4,179.5% |
| Other Income/Exp. Net | $4 | $1 | $0 | -$5 |
| Pre-Tax Income | -$40 | -$28 | -$34 | -$44 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$40 | -$28 | -$23 | -$73 |
| % Margin | -7,950.9% | -6,710.4% | -4,865.8% | -7,876.4% |
| EPS | -0.94 | -2.77 | -10.65 | -25.65 |
| % Growth | 66.1% | 74% | 58.5% | – |
| EPS Diluted | -0.94 | -2.77 | -10.65 | -25.65 |
| Weighted Avg Shares Out | 43 | 10 | 3 | 3 |
| Weighted Avg Shares Out Dil | 43 | 10 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $6 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$44 | -$29 | -$34 | -$39 |
| % Margin | -8,709.2% | -6,900.5% | -7,174.6% | -4,167.8% |